Introduction
============

Microbial resistance is a growing major public health issue and a strong concern for the medical community. Production of β-lactamases is a major means by which Gram-negative bacteria exhibit resistance to β-lactam antibiotics \[[@B1]\]. Extended spectrum β-lactamases (ESBLs) are a group of enzymes that can hydrolyze a variety of β-lactams including cephalosporins like ceftazidime, cefotaxime, ceftriaxone and monobactams like aztreonam in addition to penicillins but do not hydrolyze cephamycins like cefoxitin. Most of the ESBLs also have the ability to hydrolyze fourth generation cephalosporins like cefepime \[[@B2]\]. Until recently, ESBL-producing organisms were viewed as hospital-acquired or health care-associated pathogens, i. e. affecting patients who had typically been in hospitals or other health care facilities like nursing homes \[[@B3],[@B4]\]. In the last decades however, these infections have increasingly been recognized in patients who had no prior contact with the health care system \[[@B5],[@B6]\]. *E. coli* strains producing CTX-M type ESBLs drive this new epidemic. Reports on this newer group of ESBLs, coined CTX-M for their preferential hydrolysis of cefotaxime over ceftazidime started to emerge in *E. coli* in the late 1990s \[[@B7]\]. Studies have indicated that the genes for CTX-M type ESBLs were mobilized from the chromosomes of *Kluvera* spp. to *E. coli* plasmids through transposon-mediated events \[[@B8],[@B9]\]. Currently five clusters of CTX-M type ESBLs have been identified namely the CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-25 clusters. CTX-M-14 belonging to the CTX-M-9 cluster and CTX-M-15 belonging to the CTX-M-1 cluster are particularly associated with community-acquired isolates. In the present study, we investigated the molecular epidemiology of clinical isolates of ESBL producing *Escherichia coli* isolated from outpatients in South-Eastern Nigeria.

Materials and methods
=====================

A total of 44 clinical isolates of *E. coli* were isolated from patients attending University of Nigeria teaching hospital, Enugu (HA, n = 28) and Ebonyi State University teaching hospital Abakaliki (HB, n = 16). All isolates were characterized using standard microbiology methods and re-confirmed by MALDI-TOF \[[@B10],[@B11]\]. Extended spectrum beta lactamase enzymes were determined by double disc synergy test (DDST) method with disks of ceftazidime, cefotaxime, ceftriaxone, cefepime, and aztreonam (30 μg each) placed at a distance of 15 mm (center to center) from a disk containing amoxicillin plus clavulanic acid (20 and 10 μg, respectively) \[[@B12]\].

Isolation of genomic DNA of ESBL *E. Coli*
------------------------------------------

Genomic DNA of ESBL *E. coli* was prepared using the NucleoSpin Kit (Macherey & Nagel, Germany) following manufacturer's instructions.

Detection of resistance gene using PCR method
---------------------------------------------

Primers used for amplification of resistance genes are shown in Table [1](#T1){ref-type="table"}. Cycling conditions were as follows: initial denaturation at 94°C for 5 min, followed by 34 cycles of denaturation at 94°C for 30 s and a final extension step at 72°C for 5 min. Annealing temperatures differed according to the primer pair used and were 42°C for TEM, 47°C for SHV, 52°C for OXA-1, 58.8°C for CTX-M-1. Amplified PCR products were separated on 0.8% agarose gels, stained with ethidium bromide and visualized under UV illumination. Appropriate positive and negative controls were used in all cases \[[@B13]-[@B15]\]. Some PCR products were sequenced with 3730 sequencer (applied biosystem). The nucleotide and deduced amino acid sequence were analyzed and compared to sequence available over the Internet at the National Center for Biotechnology Information (http:IIwww.ncbi.nlm.gov). A PCR with specific primers for *aac(6′)-Ib-cr* was performed \[[@B16]\] with the primers shown in Table [1](#T1){ref-type="table"} and an annealing temperature of 45°C and followed by restriction with *Bse*GI. The genetic environment of *bla*~CTX-M~\[[@B17]\] was analyzed by PCR for ISE*cp1* upstream and ORF477 downstream with the primers shown in Table [1](#T1){ref-type="table"}.

###### 

Primers used in this study

  **Primer**     **Sequence**              **Amplicon size**   **Source**
  -------------- ------------------------- ------------------- --------------------------------
  TEM_seq        TCAACATTTCCGTGTCG         860 bp              Schlesinger *et al.*\[[@B13]\]
  TEM_rev        CTGACAGTTACCAATGCTTA                           
  SHV_seq        ATGCGTTATATTCGCCTGTG      776 bp              Schlesinger *et al.*\[[@B13]\]
  SHV_rev        AGATAAATCACCACAATGCGC                          
  CTX-M_seq      RGMAGYGYRMCGCTKYATGCSC    730 bp              Schlesinger *et al.*\[[@B13]\]
  CTX-M_rev      ARTARGTSACCAGAAYVAGCGG                         
  OXA-1_fw       GGATAAAACCCCCAAAGGAA      369 bp              Karisik E *et al.*\[[@B15]\]
  OXA-1_rev      TGCACCAGTTTTCCCATACA                           
  ISEcp1_5′      TTCAAAAAGCATAATCAAAGCC    Variable            Eckert C *et al.*\[[@B17]\]
  MA1_rev        ACYTTACTGGTRCTGCACAT                           
  CTX-M-1_54 0   GCGTGATACCACTTCACCTC      460 bp              this study
  orf477_rev     GAAGGAGAACCAGGAACCAC                          this study
  aac6-Ib-fw     TTGCGATGCTCTATGAGTGGCTA   482 bp              Park CH *et al.*\[[@B16]\]
  aac6-Ib-rev    CTCGAATGCCTGGCGTGTTT                           
  RAPD_1290      GTGGATGCGA                                    Pacheco AB et al. \[[@B18]\]

Randomly amplified polymorphic DNA (RAPD) analysis
--------------------------------------------------

RAPD was performed with all the 44 ESBL positive strains using a single primer as showed in Table [1](#T1){ref-type="table"} with annealing temperature of 37°C \[[@B18]\].

Transformation studies
----------------------

Plasmid DNA was extracted with the Qiagen Midi Kit PC100 (Qiagen, Germany). Transformation of plasmids was carried out by electroporation with *E. coli* DH5 cells as recipient strain at 2.5 kV, 25 F and 200 using a Gene--Pulser (Bio-Rad, Hemel hempstead, UK). Samples from donor and recipient strains were used as controls. Transformants growing on the selection plates (cefotaxime 2 mg/L, Sigma Aldrich Poole UK) were subjected to DDST to confirm the presence of ESBL genes and were examined for co-transfer of other antibiotic resistance determinants present in the donor clinical isolates by disk diffusion.

Results
=======

The overall result showed that of 44 *E. coli* strains studied 34 (77.2%) were from urine, 6 (13.6%) from vaginal swabs and 4 (9.0%) from wound swabs, 28 (63.6%) were from female patients. Remarkably the proportion of outpatients was very high (68%). The majority of patients (n = 42; 95.5%) were younger than 30 years.

All 44 *E. coli* strains were phenotypically confirmed as ESBL, PCR for *bla*~CTX-M~ and *bla*~CTX-M-1~ cluster was positive in all strains. Three exemplary isolates were chosen for sequencing of the full *bla*~CTX-M~ gene and sequence analysis revealed them as *bla*~CTX-M-15~. PCRs for IS*Ecp1* upstream and ORF 477 downstream of *bla*~CTX-M~ were positive in all strains. PCRs for TEM and OXA-1 beta lactamase genes were positive in 41 (93.1%) ESBL isolates. SHV could not be found in any isolate (Table [2](#T2){ref-type="table"}). Also the presence of *aac(6′)-Ib-cr* could be demonstrated in 43 strains (97.7%) by PCR and subsequent restriction analysis. No significant difference regarding the frequency of *bla*~OXA-1~, *bla*~TEM~ and *aac(6′)-Ib-cr* between ESBLs from hospital A and Hospital B could be found. RAPD analysis of ESBL strains for clonal relatedness grouped the strains into seven clonal groups (A-G). Clone A was by far the most frequent clone and found in 65.9% of all studied strains. Compared to other clones it is more frequent in hospital B (81%) than in hospital A (57.1%). PCR results in relation to clonal type are presented in Table [2](#T2){ref-type="table"}. The association of CTX-M-1 cluster genes to TEM, OXA-1 and *aac(6′)-Ib-cr* is stronger in Clone A ESBLs than in other clonal types. ESBL plasmid could be successfully transformed in 19 (43.2%) out of 44 ESBL *E. coli*. Co-resistance to gentamicin, kanamycin, tobramycin, doxycycline and trimethropim-sulfamethoxazole was observed in most transformants (Table [3](#T3){ref-type="table"}).

###### 

PCR results in relation to RAPD groups (n = 44)

  **PCR tests**      **Clona A (n = 29)**   **Other clones (n = 15)**   **Total**
  ------------------ ---------------------- --------------------------- -----------
  ^bla^~*CTX-M-1*~   29(100%)               15(100%)                    44(100%)
  ISE*cp1*           29(100%)               15(100%)                    44(100%)
  ORF 477            29(100%)               15(100%)                    44(100%)
  ^bla^~*SHV*~       0(0%)                  0(0%)                       0(0%)
  ^bla^~*TEM*~       26(89.7%)              15(100%)                    41(93.1%)
  ^bla^~*OXA-1*~     28(96.5%)              13(85%)                     41(93.1%)
  *aac*(6)′-Ib-cr    28(96.5%)              15(100%)                    3(97.7%)

###### 

Characteristics of successful transformants

  **Strains**   **Co-resistance**
  ------------- -----------------------------------------------
  10            CAZ, CTX, ATM, AMP, DO SXT, W
  14            CAZ, CTX, ATM, AMP, TOB, CN, SXT, K
  20            CAZ, CTX, ATM, AMP, DO, C, SXT, W
  29            CAZ, CTX, ATM, AMP, K, TOB, CN, SXT
  43            CAZ, CTX, ATM, AMP, SXT, DO, W, CN
  48            CAZ, CTX, ATM, AMP, K, TOB, CN, DO
  49            CAZ, CTX, ATM, AMP, K, TOB, CN DO
  50            CAZ, CTX, ATM AMP, K, TOB, CN, DO, SXT, W.
  60            CAZ, CTX, ATM, AMP, K, TOB, CN, DO
  65            CAZ, CTX, ATM, AMP, K, TOB, CN, DO
  73            CAZ, CTX, ATM, AMP, K, TOB, CN
  74            CAZ, CTX, ATM, AMP, K, TOB, CN, DO, C, SXT, W
  75            CAZ, CTX, ATM, AMP, K, TOB, CN
  77            CAZ, CTX, ATM, AMP, K, TOB, CN,
  78            CAZ, CTX, ATM, AMP, K, TOB, CN, DO
  84            CAZ, CTX, ATM, AMP, DO, SXT, W
  112           CAZ, CTX, ATM, AMP, SXT, C
  131           CAZ, CTX, ATM, AMP, K, TOB, CN, DO
  138           CAZ, CTX, ATM, AMP, K, TOB, CN

Key: *CAZ*-ceftazidime, *CTX*- cefotaxime, *ATM*- aztreonam, *AMP*- ampicillin, *TOB*- tobramycin, *SXT*- sulfametoxazole/trimethroprim, *W*- trimethroprim, *DO*- doxycycline, *CN*-gentamicin, *K*-kanamycin, *C*-chloramphenicol.

Discussions
===========

This study was carried out in two major university teaching hospitals in South-Eastern Nigeria where there is no record of investigation of molecular epidemiology of ESBL *E. coli*. Nosocomial bacterial infections constitute a substantial cause of morbidity and mortality in developing countries such as Nigeria. *E. coli* is known to be one of the major organisms causing nosocomial infections within the hospital and has also been implicated in community acquired ESBL \[[@B19],[@B20]\]. The observation of ESBL producing *E. coli* strains in this study is very alarming and this could be attributed to the indiscriminate and widespread use of antibiotics, particularly beta lactam antibiotics that are sold over the counter in pharmacy shops without doctors' prescription in Nigeria. This misuse of antibiotics might have contributed to the emergency of ESBL producing isolates. All 44 ESBL *E. coli* strains harbored ESBLs of the CTX-M-1 cluster. In three exemplary strains the CTX-M-15 ESBL could be confirmed which belongs to the CTX-M-1 cluster. These results further emphasize that this enzyme is now one of the most common CTX-M β- lactamases worldwide. In several countries CTX-M-15 is currently the most frequent ESBL in *E. coli* like in the UK, India, Spain, France, Latin America and Lebanon \[[@B20]\]. In Nigeria ESBL has been described in *Enterobacter* spp. from Western Nigeria several years ago \[[@B21]\] and CTX-M-15 ESBL in *K. pneumoniae* from the same region four years later \[[@B22]\] while ESBL was also reported in *E. coli* from South Eastern Nigeria this same year \[[@B23]\] but no description of CTX-M-15 ESBL from outpatients has been reported. Recently CTX-M-15 ESBL producing *E. coli* was reported from hospital patients in Osogbo in Western Nigeria \[[@B24]\]. CTX-M-15 has also been reported from other African countries like Egypt \[[@B25]\], Algeria \[[@B26]\], Tunisia \[[@B27]\], Tanzania \[[@B28]\], and Cameroon \[[@B29]\]. One of the most alarming findings of our study is that most ESBL isolates were detected in urine from young outpatients; urine was the source of 81.8% of ESBL strains, 68.2% of patients were of an age below 30 years. This strongly indicates that CTX-M-15 carrying *E. coli* strains can cause community-acquired urinary tract infections and that those ESBL strains are not only present in a hospital environment but also in the community population of this area of Nigeria. Similar observations have been made also in other parts of the world \[[@B5],[@B6]\].

Typing of isolates via RAPD grouped the isolates into seven different clones. Seven strains could not be typed by this method and the majority of ESBL *E. coli* strains studied in this work belongs to a single clone as determined by RAPD. Of particular interest is that this clone A was detected in two hospitals located more that 70 km away from each other. One possible explanation is patient-to-patient transmission in both hospitals and introduction of clone A into another hospital by patient transfer. Hospital A serves as referral hospital for patients in hospital B with serious medical problems. A certain degree of inter-hospital spread was discovered because two patients with clone A ESBLs were known to have visited both hospitals during our study period. Thus, it is of high importance to apply specific infection control measures like hand disinfection in hospitals. Considering that also clone A ESBL isolates were found in young outpatients, another possible explanation might be that clone A occurs rather frequently in the population of this area. If so, it would be worth the effort to exclude a possible common source like drinking water or food products.

As observed worldwide for CTX-M-15 ESBL *E. coli* strains, we found a high association of CTX-M-1 cluster ESBLs with IS*Ecp1* upstream and ORF 477 downstream of the gene, with the presence of TEM and OXA-1 beta lactamases and with the detection of *aac(6′)-Ib-cr*. The latter gene mediates resistance to tobramycin and decreased susceptibility to ciprofloxacin \[[@B30]\]. Thus it is one of several factors responsible for multi-drug resistance also to non-beta lactam antibiotics in ESBL strains.

Conclusions
===========

For the first time ESBL *E. coli* strains could be demonstrated from Southeastern Nigeria with CTX-M-1 cluster enzymes present in all isolates. Most of the ESBL strains also carried TEM, OXA-1 and *aac(6′)-Ib-cr* and the majority of strains were isolated from outpatients below the age of 30. Based on our findings we suggest that antimicrobial resistance surveillance network be established in the two hospitals to monitor the trends and new types of resistance mechanism in Southeastern, Nigeria.
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